In recent years, the biopharmaceutical sector has witnessed a notable shift in financing strategies, particularly concerning synthetic royalty transactions. Traditionally, these agreements—where investors provide capital to drug developers in exchange for a share of future sales—have been secured by specific product assets, such as intellectual property rights. However, recent data indicates a resurgence of unsecured synthetic royalties, marking a departure from the prevailing trend.
According to the “Fourth Annual Synthetic Royalty and Drug Development Financing Study,” there has been a consistent trend towards securing these transactions with product assets. In 2023 and 2024, all such deals were secured. However, 2025 saw the first unsecured public synthetic royalty transaction since 2022, suggesting a potential shift in the market’s risk appetite. ([cov.com](https://www.cov.com/-/media/files/corporate/publications/2026/06/fourth-annual-synthetic-royalty-and-drug-development-financing-study.pdf?utm_source=openai))
Royalty Pharma, a prominent player in this domain, has been instrumental in shaping these financing structures. The company’s 2023 Annual Report outlines their approach to synthetic royalties, emphasizing the creation of new royalties on approved or late-stage development therapies with strong commercial potential. These agreements often include contingent milestone payments and may involve funding ongoing research and development in exchange for future royalties. ([annualreports.com](https://www.annualreports.com/HostedData/AnnualReportArchive/r/NASDAQ_RPRX_2023.pdf?utm_source=openai))
The re-emergence of unsecured synthetic royalties could be attributed to several factors. Investors may be seeking higher returns by accepting greater risk, especially in a competitive market where securing assets can be complex and time-consuming. Additionally, drug developers might prefer unsecured arrangements to retain greater control over their assets and avoid encumbering their intellectual property.
While this trend offers potential benefits, it also introduces increased risk for investors. Without collateral, the recovery of invested capital becomes more challenging if the drug fails to achieve commercial success. Therefore, thorough due diligence and a comprehensive understanding of the associated risks are imperative for stakeholders considering unsecured synthetic royalty agreements.
As the biopharmaceutical industry continues to evolve, the dynamics of financing strategies like synthetic royalties will likely adapt to meet the changing needs of investors and developers. The recent shift towards unsecured transactions underscores the importance of flexibility and risk assessment in structuring these financial instruments.